|1.||Masuyama, Takeshi: 4 articles (03/2010 - 01/2008)|
|2.||Bernard, Bruce K: 4 articles (03/2010 - 01/2008)|
|3.||Kodama, Terutaka: 4 articles (03/2010 - 01/2008)|
|4.||Tsubuku, Shoji: 4 articles (03/2010 - 01/2008)|
|5.||Kim, Tae-Yoon: 3 articles (08/2015 - 01/2008)|
|6.||Watanabe, Tatsuo: 3 articles (03/2012 - 12/2003)|
|7.||Fushiki, Tohru: 3 articles (03/2012 - 12/2003)|
|8.||Yazawa, Susumu: 3 articles (03/2012 - 12/2003)|
|9.||Watanabe, Eri: 3 articles (01/2008 - 01/2008)|
|10.||Lee, Eun-Jung: 2 articles (08/2015 - 05/2010)|
|1.||Body Weight (Weight, Body)
01/01/2015 - "Both capsiate treatments further promoted muscle mass gain, and the higher dose also reduced body weight gain and abdominal fat content. "
08/01/2011 - "The body weight in capsiate and exercise groups was significantly lower than that of control group. "
03/01/2010 - "Test animals received either dihydrocapsiate, 100, 300, or 1000 mg/kg/day, or vehicle (medium-chain triglyceride) by gavage and were observed for antemortem and postmortem signs of toxicity including changes in clinical signs, body weights, food consumption, water intake, ophthalmology, clinical pathology (clinical chemistry, hematology, urinalysis), tissue findings (macroscopic and microscopic examination), as well as organ weights. "
01/01/2008 - "There were no changes observed in clinical signs, body weight, food consumption, water intake, ophthalmology, urinalysis, hematology, or blood chemistry that were attributable to the administration of dihydrocapsiate. "
01/01/2008 - "Test subjects received either dihydrocapsiate, 100, 300, or 1000 mg/kg/day, or vehicle by gavage and were observed for antemortem and postmortem signs of toxicity, which included changes in clinical signs, body weights, food consumption, water intake, ophthalmology, clinical pathology (clinical chemistry, hematology, urinalysis), tissue findings (macroscopic and microscopic examination), as well as organ weights. "
12/01/2003 - "In the present study, we report that 2-wk treatment of capsiate increased metabolic rate and promoted fat oxidation at rest, suggesting that capsiate may prevent obesity. "
01/01/2015 - "These findings demonstrate that, in addition to its anti-obesity effect, capsiate supplementation improves oxidative metabolism in exercising muscle, which strengthen this compound as a natural compound for improving health. "
05/15/2014 - "These data present capsiate as a helpful candidate to enhance both muscle performance and oxidative phosphorylation during exercise, which could constitute a nutritional approach for improving health and preventing obesity and associated metabolic disorders. "
|3.||Atopic Dermatitis (Atopic Eczema)
08/01/2015 - "In this study, we investigated the effect of capsiate on atopic dermatitis, mouse CD4+ T cells, and mast cell activation. "
08/01/2015 - "Taken together, our results suggest that capsiate might be a good candidate molecule for the treatment of allergic diseases such as atopic dermatitis. "
08/01/2015 - "Capsiate inhibited DNFB-induced atopic dermatitis in NC/Nga mice. "
08/01/2015 - "Capsiate Inhibits DNFB-Induced Atopic Dermatitis in NC/Nga Mice through Mast Cell and CD4+ T-Cell Inactivation."
05/01/2010 - "Therefore, capsiate may protect the skin from UVB-induced adverse effects and these results provide a molecular basis for understanding its effects on inflammation and angiogenesis."
03/01/2012 - "Like capsaicin, capsiate is thought to enhance energy metabolism by activating the sympathetic nervous system and suppressing inflammation, but the underlying mechanisms for this are uncertain. "
05/01/2010 - "Capsiate inhibits ultraviolet B-induced skin inflammation by inhibiting Src family kinases and epidermal growth factor receptor signaling."
01/01/2015 - "Regardless of the dose, capsiate treatments markedly disturbed basal bioenergetics in vivo including intracellular pH alkalosis and decreased phosphocreatine content. "
12/01/2009 - "During muscle stimulation, pH(i) showed a larger alkalosis in the capsiate group suggesting a lower glycolysis and a compensatory higher aerobic contribution to ATP production. "
|5.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|7.||Epidermal Growth Factor Receptor (EGF Receptor)
|9.||Dihydrotachysterol (AT 10)
|10.||Adenosine Triphosphate (ATP)